Core Viewpoint - The healthcare stocks in mainland China have experienced a significant pullback since early last month, with the Hang Seng Healthcare Index and the CSI 300 Healthcare Index declining by 12% and 9% respectively, compared to a 2% drop in the Hang Seng Index and a 1% increase in the CSI 300 Index [1] Group 1: Market Influences - The decline in healthcare stocks is attributed to multiple factors, including heightened US-China tensions and increased geopolitical risk premiums prompting profit-taking by investors [1] - The introduction of a milder version of the US "Biosecurity Act" attached to next year's National Defense Authorization Act has raised uncertainties regarding pharmaceutical outsourcing services [1] - Concerns persist regarding potential increased regulation from the US, such as restrictions on authorized transactions with China or limitations on clinical data from China, which could impact the biotech and pharmaceutical sectors [1] Group 2: Market Sentiment and Valuation - The anticipated outcomes of the national medical insurance drug list price negotiations and the legislative progress of the "Biosecurity Act" are expected to influence market sentiment [1] - Despite the recent stock price declines, industry valuations and market expectations for business development transactions are returning to more reasonable levels, with no substantial deterioration in the industry's fundamental performance observed [1] - The recent pullback in stock prices may provide favorable conditions for performance in the upcoming year [1] Group 3: Preferred Stocks - The company identifies preferred stocks including CanSino Biologics (09926), Hansoh Pharmaceutical (03692), and WuXi AppTec (603259) (02359) [1] - The company also expresses optimism for Innovent Biologics (01801) and Heng Rui Medicine (600276) (01276) [1]

Core Viewpoint - The healthcare stocks in mainland China have experienced a significant pullback since early last month, with the Hang Seng Healthcare Index and the CSI 300 Healthcare Index declining by 12% and 9% respectively, compared to a 2% drop in the Hang Seng Index and a 1% increase in the CSI 300 Index [1] Group 1: Market Influences - The decline in healthcare stocks is influenced by multiple factors, including heightened US-China tensions and increased geopolitical risk premiums prompting profit-taking by investors [1] - The inclusion of a milder version of the US "Biosecurity Act" in next year's National Defense Authorization Act has raised uncertainties regarding pharmaceutical outsourcing services [1] - Concerns persist regarding potential increased US regulations that may restrict authorized transactions with China or limit clinical data from Chinese sources, impacting the biotech and pharmaceutical sectors [1] Group 2: Market Sentiment and Valuation - Recent authorized transactions have failed to boost market sentiment, and the lack of strong industry-level positive catalysts for the remainder of the year may limit stock price momentum [1] - The anticipated results of national medical insurance drug price negotiations and the legislative progress of the "Biosecurity Act" are expected to influence market sentiment [1] - Despite the pullback, industry valuations and market expectations for business development transactions are returning to more reasonable levels, with no substantial deterioration in the industry's solid fundamentals observed [1] Group 3: Investment Recommendations - The recent stock price decline is viewed as providing favorable conditions for performance in the upcoming year [1] - Preferred stocks identified by the company include CanSino Biologics (09926), Hansoh Pharmaceutical (03692), and WuXi AppTec (02359), with additional positive outlooks for Innovent Biologics (01801) and Hengrui Medicine (01276) [1]

Core Insights - The CXO (Contract Research Organization) sector in A-shares shows strong growth, with 20 out of 29 listed companies reporting year-on-year revenue increases in the first three quarters [1] - In the third quarter alone, 21 companies achieved year-on-year revenue growth, driven by international demand for innovative drugs and a supportive policy environment [2] Industry Overview - The innovative drug industry is experiencing a dual boost from policy support and surging demand, which is activating new drug research and development needs, benefiting the CXO sector [2] - The National Healthcare Security Administration and the National Health Commission issued measures to support high-quality development of innovative drugs, proposing 16 policies to enhance the entire chain of support [2] Company Performance - Several CXO companies reported robust order backlogs for the first three quarters. For instance, WuXi AppTec reported a backlog of 59.88 billion yuan, a 41.2% increase year-on-year [2] - Innosilicon reported a nearly 20% increase in order amounts compared to the end of 2024, while Haoyuan reported a 50% year-on-year increase in its small molecule business orders [3] Market Trends - The first half of the year saw a surge in Chinese innovative drugs going global, with total foreign licensing transactions reaching $60 billion, accounting for 99% of global related transactions [3] - Morgan Stanley's healthcare research head in Greater China anticipates stable long-term growth in foreign licensing transactions for Chinese innovative drugs, with multinational companies likely to be more active in acquiring Chinese assets [3] Future Outlook - The CXO industry is expected to benefit from a combination of demand recovery and structural upgrades, with policies, capital, and technology contributing to a more certain industry development [3] - The industry is transitioning from "scale dividends" to "technology premiums," with technological iteration and process innovation becoming the core of competition [3]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [1] Core Views - The investment logic in the pharmaceutical sector is shifting from policy pressure to innovation-driven growth, with the "14th Five-Year Plan" directly supporting the development of innovative drugs and medical devices [8][26] - The industry is witnessing a transition from rapid following to original innovation, as demonstrated by Chinese companies showcasing their global competitiveness and pipeline value at the 2025 ESMO conference [8][26] - The recent approval of innovative drugs and the successful listing of companies on the STAR Market indicate a supportive capital market for innovative pharmaceutical enterprises [8][26] Industry Review - The pharmaceutical and biotechnology industry index increased by 1.89%, ranking 20th among 31 primary industries, underperforming the CSI 300 index which rose by 2.80% [5][16] - The sub-industries of medical research outsourcing and vaccines showed the highest gains, with increases of 5.26% and 4.19% respectively, while medical devices and traditional Chinese medicine experienced declines of 1.21% and 0.56% [5][16] - As of October 31, 2025, the industry’s PE (TTM, excluding negative values) was 30.67x, up from 30.08x in the previous period, indicating an upward valuation trend but still below the average [21] Company Dynamics - A total of 36 listed companies in the pharmaceutical and biotechnology sector experienced a net reduction in shareholder holdings amounting to 805 million yuan, with 4 companies increasing holdings by 120 million yuan and 32 companies reducing holdings by 925 million yuan [5][6] - Among the 501 tracked companies, 499 have disclosed their performance for the first three quarters of 2025, with 53 companies reporting a net profit growth of 100% or more, and 69 companies reporting growth between 30% and 100% [6] Investment Recommendations - Focus on companies with strong positions in innovative drugs and cutting-edge technology platforms, particularly those involved in ADC, bispecific/multispecific antibodies, and cell therapy, which can provide high potential for international market expansion [8] - Pay attention to the CXO industry, which is expected to see increased demand due to the recovery of innovative drug development and commercialization, especially for leading companies with strong service capabilities in new technology areas [8]

Market Overview - A-shares rebounded in the afternoon on November 3, with all three major indices turning positive by the close; the Shanghai Composite Index rose by 0.55% to 3976.52 points, the Shenzhen Component increased by 0.19% to 13404.06 points, and the ChiNext Index gained 0.29% to 3196.87 points [1] - The total trading volume in the Shanghai and Shenzhen markets was 21.33 billion yuan, a decrease of 2.17 billion yuan from the previous day [1] Sector Performance Coal and Oil - The coal sector saw significant gains, with companies like Antai Group and Zhongmei Energy hitting the daily limit, and others like Shanxi Black Cat and Jin控煤业 rising over 4% [4][6] - The oil sector also performed well, with Huibo Group and Intercontinental Oil hitting the daily limit, and China National Offshore Oil Corporation and China Petroleum rising over 4% [7] AI Applications - The AI application sector was notably active, with stocks like Fushi Holdings and Xinghuan Technology rising over 10%, and several others hitting the daily limit [12][14] Nuclear Power - The nuclear power concept experienced a surge, with significant advancements in thorium-based molten salt reactor technology reported by the Chinese Academy of Sciences, marking a key development in nuclear energy [10] Key Insights - The current prices of thermal coal and coking coal remain at historical lows, providing room for a rebound due to supply-side policies and seasonal demand increases [6] - The "three barrels of oil" (China National Petroleum, Sinopec, and CNOOC) are expected to continue increasing their oil and gas equivalent production, with respective growth rates of 2.6%, 2.2%, and 6.7% projected for the first three quarters of 2025 [7] - The AI-driven content creation market is projected to grow significantly, with over 3000 new works expected in the first half of 2025, indicating a robust demand for AI applications in media [14]

Core Viewpoint - WuXi AppTec (603259.SH) reported a stock price of 96.41 CNY, reflecting a decline of 3.01% [1] Group 1: Company Performance - Western Securities analysts Li Mengyuan and Xu Ziyue released a report on October 29, stating that WuXi AppTec has raised its full-year performance guidance [1] - The report emphasizes a further focus on core business to enhance profit margins [1] - The analysts maintained a "Buy" rating for the company [1]

Market Overview - Hong Kong stocks opened positively in November, with major indices rising, and the Hang Seng Index closing at 26,158.36 points, up 0.97% or 251.71 points, with a total turnover of HKD 228.68 billion [1] - The Hang Seng China Enterprises Index increased by 0.98% to 9,258.73 points, while the Hang Seng Tech Index rose by 0.24% to 5,922.48 points [1] Blue Chip Performance - Chow Tai Fook (01929) led the blue-chip decline, falling 8.67% to HKD 13.9, impacting the Hang Seng Index by 4.04 points [2] - AIA Group (01299) rose 5.96%, contributing 75.25 points to the index, while Wanzhou International (00288) increased by 4.69%, adding 4.62 points [2] Sector Performance Technology Sector - Technology stocks showed mixed results, with Alibaba down 1.15% and Tencent down 0.16%, while Kuaishou rose 1.52% [3] Oil Sector - Oil stocks experienced a broad increase, with China National Offshore Oil Corporation (00883) up 3.49% and China Petroleum (00857) up 3.37%, following OPEC+'s announcement to pause production increases in early 2024 [3] Coal Sector - Coal stocks generally rose, with China Qinfa (00866) up 7.53% and Yanzhou Coal (01171) up 4.69%, driven by seasonal demand and safety production assessments [4] AI Application Sector - AI application stocks were active, with Fenbi (02469) surging 10.36% after announcing a share buyback plan, reflecting strong market interest in AI education products [4][10] Gold and Jewelry Sector - Gold mining and jewelry stocks fell sharply, with Chow Tai Fook down 8.67% and Lao Pu Gold (06181) down 7.16%, following new tax policies affecting gold trading [6] Automotive Sector - The automotive sector showed varied performance, with XPeng Motors (09868) up 4.59% and NIO (09866) up 4.21%, supported by strong October delivery figures for new energy vehicles [7] Notable Stock Movements - Minglue Technology (02718) debuted with a significant rise of 106.1%, closing at HKD 290.6, indicating strong investor interest in data intelligence applications [8] - WuXi AppTec (02126) surged 16.09% due to positive developments regarding its CAR-T cell therapy's inclusion in commercial health insurance [9]

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry [1] Core Insights - The rhythm of innovative drug licensing-out transactions has recovered, with a total of 103 transactions and a total amount of $92.03 billion in the first three quarters of 2025, representing a 77% increase compared to the total amount for 2024 [2] - The research and CXO sectors continue to lead the recovery in the pharmaceutical industry, with significant profit growth in these areas [4] - The medical device bidding market has shown a steady recovery, with a year-on-year growth of 29.8% in the third quarter of 2025 [5] - The self-immune field has seen breakthroughs in overseas licensing, indicating a growing alignment with global R&D trends [6] - The weight loss market is experiencing competitive mergers and acquisitions, highlighting its attractiveness and potential impact on Chinese companies [7] - Trends in respiratory infectious diseases are expected to influence the demand for detection and treatment medications [8] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry outperformed the CSI 300 index by 1.74 percentage points in the last week, ranking 9th among 31 primary industry indices [21] - In the last month, the pharmaceutical industry underperformed the CSI 300 index by 1.83 percentage points, ranking 24th [25] 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical industry index has a current PE (TTM) of 38.80, above the five-year historical average of 31.26 [42] 3. Recent Research Achievements - The report highlights various recent research outputs, including weekly industry reports and insights on innovative drug licensing trends [48] 4. Recent Industry Policies and News - The National Healthcare Security Administration has initiated reforms for immediate settlement of medical insurance funds, aiming for 80% coverage by the end of 2025 [50] - Recent news includes significant breakthroughs in GLP-1 therapies and the approval of new drugs for chronic hepatitis B [51][52] 5. Recommended Companies and Profit Forecasts - The report provides a list of recommended companies with their respective EPS and PE ratios, indicating a positive outlook for several firms in the pharmaceutical sector [10]

化学偶联物(TIDES)将有助于公司增长，TIDES在2025年前三季收入同比增121%至78亿元，主要得益于 TIDES积压订单年增17%。鉴于海外客户对TIDES的需求持续增长，该行将2026年和2027年的总收入预 测分别上调2%和3%，达到519亿元和585亿元；由于毛利率提高和营运支出与销售额比率下降，将2026 及2027年核心盈利预期分别上调9%及12%至153及177亿元。 智通财经APP获悉，建银国际发布研报称，上调药明康德(02359)目标价7.4%，从122港元升至131港 元，维持"跑赢大市"评级。该行表示，尽管"美国生物安全法案2.0"可能即将生效，但除继续为GLP-1靶 向药物提供客户服务外，该公司仍持续拓展药物范围。该行表示，该公司2025年第三季业绩超过预期， 纯利从2024年同期的23亿元人民币(下同)增长至35亿元，总收入同比增15%至121亿元。 ...

智通财经APP获悉，建银国际发布研报称，上调药明康德(02359)目标价7.4%，从122港元升至131港 元，维持"跑赢大市"评级。该行表示，尽管"美国生物安全法案2.0"可能即将生效，但除继续为GLP-1靶 向药物提供客户服务外，该公司仍持续拓展药物范围。该行表示，该公司2025年第三季业绩超过预期， 纯利从2024年同期的23亿元人民币(下同)增长至35亿元，总收入同比增15%至121亿元。 化学偶联物(TIDES)将有助于公司增长，TIDES在2025年前三季收入同比增121%至78亿元，主要得益于 TIDES积压订单年增17%。鉴于海外客户对TIDES的需求持续增长，该行将2026年和2027年的总收入预 测分别上调2%和3%，达到519亿元和585亿元；由于毛利率提高和营运支出与销售额比率下降，将2026 及2027年核心盈利预期分别上调9%及12%至153及177亿元。 ...